Harrow Reports 2025 Second Quarter Revenue Growth

Published on August 12, 2025
NASHVILLE Tenn.—Harrow, Inc. (Nasdaq: HROW), a leading eyecare pharmaceutical company engaged in the development, and commercialization of ophthalmic pharmaceutical products for the North American market, yesterday announced its second quarter 2025 financial results ended June 30, 2025. The company reported total Q2 revenues of $63.7 million, a 30 percent increase compared with $48.9 million recorded in the prior-year period, as well as a sequential increase of 33 percent from the first quarter 2025 revenues.
Continue reading on website
Other news

First-ever CVI awareness day to be held in Boston in September

August 11, 2025
Boston event will shed light on cerebral/cortical visual impairment (CVI), a leading cause of pediatric blindness

Pediatric myopia and the urgent need for early intervention

August 12, 2025
One in 3 children worldwide has myopia, and the prevalence is rising so steadily that if it continues as predicted, there will be more than 740 million pediatric cases by 2050.